Rockefeller Capital Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
Rockefeller Capital Management's CLDX Position: Q3 2026 in Review
Rockefeller Capital Management reduced its Celldex Therapeutics (CLDX) stake by 0.23% in Q3 2026, selling an estimated $115 and leaving 1,293 shares worth $41.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3557.
Rockefeller Capital Management first reported a position in CLDX in Q3 2021 and has held it in 10 quarters since. The position peaked at $48.2K in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Rockefeller Capital Management held 1,293 shares of Celldex Therapeutics worth $41.9K as of Q3 2026.
- Rockefeller Capital Management sold 3 Celldex Therapeutics shares in Q3 2026, an estimated $115.
- Celldex Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3557 holding.
- Rockefeller Capital Management first reported a position in Celldex Therapeutics in Q3 2021 and has held it in 10 quarters since.
- Rockefeller Capital Management's Celldex Therapeutics position peaked at $48.2K in Q2 2026.
- 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.